Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
Explore this paper's citation graph
Summary
Panitumumab significantly improved PFS with manageable toxicity in patients with chemorefractory colorectal cancer and was well tolerated.
- Type
- article
- Published
- 2007-05-01
- Cited by
- 1,958
- References
- 32
- OpenAlex
- https://openalex.org/W2097121246
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:45223676
Keywords
Panitumumab, Medicine, Internal medicine, Colorectal cancer, Hazard ratio
References
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
- Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
- Preclinical discovery and clinical validation of predictive markers of response to cetuximab (Erbitux™) in metastatic colorectal cancer
- Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?
- A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma
- Fully Human Therapeutic Monoclonal Antibodies
- CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR.
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
- Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.
- Global Cancer Statistics, 2002
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
- Radiation therapy and tamoxifen: concurrent or sequential? That is the question.
- High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
- Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.
- Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
- A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
- Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
- FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
- New guidelines to evaluate the response to treatment in solid tumors
- Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.
Cited by
- K-ras mutations in colorectal cancer: a practice changing discovery.
- Des mutations de KRAS aux mutations de RAS : vers une meilleure définition de la réponse aux anticorps anti-EGFR dans le cancer colorectal métastatique
- Lebermetastasen kolorektaler Karzinome
- Developments in Epidermal Growth Factor Receptor-Targeting Therapy for Solid Tumors: Focus on Matuzumab (EMD 72000)
- Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
- Review article: current management of metastatic colorectal cancer – the evolving impact of targeted drug therapies
- An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.
- Electrolyte disorders related to EGFR-targeting drugs.
- Skin toxicities associated with epidermal growth factor receptor inhibitors
- Update on Anti-EGFR Therapy
- Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature.
- The Cost-Effectiveness of Combination Treatment Consisting of Either Cetuximab or Panitumumab plus FOLFIRI versus Treatment with Bevacizumab plus FOLFIRI as First-Line Treatment for KRAS Wild-Type Metastatic Colorectal Cancer Patients in Ontario
- Past, present and future of targeted therapy in solid tumors.
- EPIDERMAL GROWTH FACTOR RECEPTOR TARGETED THERAPIES FOR SOLID TUMOURS
- Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients
- Predictive tests for individualization of pharmacological cancer treatment.
- Systemic cancer therapy: achievements and challenges that lie ahead
- Markers of resistance to anti-EGFR therapy in colorectal cancer.
- mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes
- Incidence and Risk of Treatment-Related Mortality with Anti-Epidermal Growth Factor Receptor Monoclonal Antibody in Cancer Patients: A Meta-Analysis of 21 Randomized Controlled Trials
Related papers
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- KRAS mutations: analytical considerations.
- A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
- KRAS Mutation Testing in Human Cancers: The Pathologist's Role in the Era of Personalized Medicine
- Cancer: Pinprick diagnostics
- KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.
- New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
- Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC).